Saturday 17 October 2026
Export SRPT’s income statement to Excel — free account
Sarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
17.06
0.73
−4.10%
Follow SRPT
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 2 | 2 | 6 | 3 | 2 | 5 | 5 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.63 | 0.00 |
Altman Z-Score |
4.10 | 3.21 | 6.18 | 3.64 | 2.64 | 1.11 | 1.21 | 1.13 | 2.73 | (0.97) |
P/S ratio |
139.35 | 22.16 | 24.02 | 24.94 | 24.61 | 10.43 | 11.72 | 7.15 | 6.08 | 0.98 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 99.68 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(4.54) | 3.40 | 2.24 | (1.52) | 0.53 | 0.62 | (1.01) | (0.75) | 1.44 | (2.78) |
P/Operating CF |
(16.74) | (110.31) | (59.06) | (57.99) | (76.15) | (249.53) | (118.31) | (162.64) | 125.59 | 16.42 |
Beneish M-Score |
(0.27) | 21.77 | (0.70) | (2.41) | (3.32) | (1.97) | (2.80) | (1.73) | (1.39) | (3.41) |
P/B ratio |
4.04 | 4.34 | 7.00 | 11.61 | 17.45 | 7.89 | 28.40 | 10.34 | 7.57 | 1.89 |
Price to Tangible BV |
4.14 | 4.42 | 7.08 | 11.79 | 17.77 | 8.01 | 29.39 | 10.50 | 7.63 | 1.91 |
EV/Sales |
107.33 | 17.97 | 21.55 | 23.80 | 22.90 | 9.00 | 11.25 | 6.80 | 6.01 | 0.97 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 53.05 | 0.00 |
EV/Operating CF |
(4.26) | (11.97) | (16.69) | (19.86) | 115.07 | (14.25) | (32.28) | (16.87) | (55.56) | (10.39) |
EV/FCF |
(4.14) | (21.67) | (14.32) | (17.45) | 92.74 | (16.53) | (29.18) | (17.38) | (32.41) | (6.77) |
Quick Ratio |
4.43 | 12.55 | 7.04 | 4.59 | 4.90 | 5.01 | 3.56 | 3.18 | 2.67 | 1.22 |
Current Ratio |
4.95 | 13.91 | 8.21 | 5.55 | 5.97 | 5.75 | 4.13 | 3.95 | 4.20 | 2.32 |
Net Debt/EBITDA |
1.20 | 3.94 | 2.22 | 0.64 | 1.72 | 2.38 | 0.85 | 1.63 | (1.01) | 0.17 |
Debt/Assets |
3.81% | 32.96% | 25.61% | 37.85% | 33.96% | 35.32% | 49.84% | 37.92% | 28.69% | 24.75% |
Debt/Equity |
0.05 | 0.55 | 0.41 | 0.84 | 1.33 | 1.20 | 4.05 | 1.44 | 0.74 | 0.73 |
Asset Turnover |
0.02 | 0.18 | 0.20 | 0.22 | 0.22 | 0.23 | 0.30 | 0.39 | 0.53 | 0.60 |
Operating CF/Net income |
0.92 | 4.58 | 1.07 | 0.64 | (0.19) | 1.06 | 0.46 | 0.93 | (0.87) | 0.29 |
Capex/Depreciation |
(1.21) | 14.41 | (13.37) | (2.43) | 0.96 | 1.61 | (1.03) | (8.24) | 57.56 | (2.80) |
Interest Coverage |
(498.56) | (94.88) | (22.34) | (31.24) | (75.64) | (899.63) | (19.34) | — | — | — |
| (101.42%) | (9.00%) | (39.74%) | (77.29%) | (70.15%) | (49.57%) | (107.16%) | (86.15%) | 19.71% | (53.47%) | |
| (76.59%) | (5.85%) | (24.54%) | (41.28%) | (23.05%) | (13.66%) | (22.42%) | (16.77%) | 6.51% | (19.51%) | |
ROIC |
(686.01%) | (75.97%) | (77.00%) | (115.04%) | 0.00% | 0.00% | 0.00% | (39.75%) | 10.40% | (42.46%) |
Return on Tangible Assets |
(79.58%) | (4.28%) | (26.82%) | (53.61%) | (24.52%) | (17.88%) | (33.21%) | (24.90%) | 8.77% | (39.90%) |
Average Days of Receivables |
352.01 | 69.58 | 59.47 | 87.10 | 68.49 | 79.56 | 83.96 | 117.52 | 115.52 | 66.12 |
Research and Development Expense of Revenue |
3,473.01% | 107.84% | 133.49% | 147.28% | 133.74% | 109.87% | 94.01% | 70.57% | 42.30% | 69.24% |
Selling, General and Administrative Expense of Revenue |
1,544.90% | 79.36% | 69.02% | 74.79% | 58.85% | 40.27% | 48.38% | 38.76% | 29.33% | 22.37% |
Intangible Assets out of Total Assets |
0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
552.70% | 19.71% | 16.65% | 20.64% | 20.01% | 16.23% | 24.97% | 14.68% | 9.69% | 5.61% |
Graham Net Nets |
0.21 | 0.21 | 0.11 | 0.05 | 0.02 | 0.05 | (0.02) | 0.02 | 0.06 | 0.15 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.76 | 0.00 |
Earnings Yield |
(19.56%) | (1.32%) | (4.97%) | (7.49%) | (4.14%) | (5.71%) | (6.43%) | (6.34%) | 2.01% | (33.15%) |
Free Cash Flow Yield |
(18.59%) | (3.74%) | (6.27%) | (5.47%) | 1.00% | (5.22%) | (3.29%) | (5.47%) | (3.05%) | (14.64%) |
Revenue per Share |
0.11 | 2.63 | 4.54 | 5.17 | 6.93 | 8.64 | 10.66 | 13.46 | 20.01 | 21.96 |
Operating CF per Share |
(5.05) | (3.94) | (5.87) | (6.20) | 1.38 | (5.45) | (3.72) | (5.42) | (2.16) | (2.05) |
Capex per Share |
(0.14) | 1.76 | (0.92) | (0.81) | 0.33 | 0.75 | (0.37) | 0.16 | (1.55) | (1.10) |
Free Cash Flow per Share |
(5.19) | (2.18) | (6.79) | (7.01) | 1.71 | (4.70) | (4.08) | (5.26) | (3.71) | (3.15) |
Cash per Share |
6.75 | 18.35 | 17.72 | 15.28 | 24.87 | 26.04 | 22.72 | 18.14 | 14.25 | 9.39 |
Shareholders Equity per Share |
6.91 | 13.42 | 15.58 | 11.11 | 9.77 | 11.42 | 4.40 | 9.30 | 16.07 | 11.39 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.91 | 13.42 | 15.58 | 11.11 | 9.77 | 11.42 | 4.40 | 9.30 | 16.07 | 11.39 |
Free Cash Flow |
(252.69) | (128.21) | (449.82) | (516.09) | 133.33 | (381.97) | (357.60) | (486.34) | (352.74) | (315.33) |
Working Capital |
298.05 | 1,140.31 | 1,252.49 | 1,204.15 | 2,069.17 | 2,151.37 | 1,938.26 | 1,925.67 | 2,341.78 | 1,442.65 |
Capital Expenditures |
(6.87) | 103.79 | (61.16) | (59.63) | 25.87 | 61.20 | (32.25) | 14.66 | (146.96) | (109.85) |
Net Current Asset Value |
286.06 | 709.90 | 816.38 | 464.28 | 262.24 | 384.13 | (185.55) | 174.09 | 638.03 | 328.86 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 52.43 | 0.00 |
Capex to Sales |
1.27 | (0.67) | 0.20 | 0.16 | (0.05) | (0.09) | 0.03 | (0.01) | 0.08 | 0.05 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 53.01 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.15 | 0.17 | 0.05 | 0.19 | 0.14 | 0.20 | 0.17 | (0.01) | (0.01) | 0.11 |
Cash ROIC |
(37.08%) | (5.58%) | (17.12%) | (19.60%) | 3.59% | (9.19%) | (9.09%) | (12.89%) | (8.78%) | (10.84%) |
Accounts Receivable Turnover |
1.18 | 8.91 | 7.67 | 5.44 | 5.62 | 5.52 | 5.08 | 4.04 | 3.80 | 4.40 |
Accounts Payable Turnover |
0.00 | 0.39 | 1.62 | 1.11 | 0.71 | 1.03 | 1.62 | 1.15 | 1.68 | 3.39 |
Inventory Turnover |
0.00 | 0.15 | 0.33 | 0.38 | 0.31 | 0.46 | 0.72 | 0.57 | 0.59 | 1.01 |
Average Days of Payables |
107,295.54 | 420.30 | 361.11 | 439.23 | 639.74 | 288.62 | 249.98 | 400.38 | 245.29 | 122.09 |
Days of Inventory on Hand |
46,304.41 | 4,150.12 | 1,339.09 | 1,105.46 | 1,335.80 | 700.34 | 531.82 | 783.83 | 857.84 | 397.67 |
Average Receivables |
4.60 | 17.35 | 39.26 | 69.96 | 96.11 | 127.17 | 183.81 | 307.48 | 501.16 | 500.11 |
Average Payables |
24.96 | 19.08 | 21.15 | 50.96 | 89.59 | 93.92 | 86.31 | 130.40 | 189.68 | 247.64 |
Average Inventory |
48.41 | 48.21 | 104.53 | 148.41 | 201.67 | 209.09 | 195.09 | 263.41 | 536.41 | 832.35 |
Average Assets |
348.94 | 866.03 | 1,475.02 | 1,732.45 | 2,403.77 | 3,066.35 | 3,138.17 | 3,196.47 | 3,613.87 | 3,656.44 |
Average Common Equity |
263.52 | 562.95 | 910.75 | 925.23 | 789.97 | 844.88 | 656.48 | 622.14 | 1,193.54 | 1,334.18 |
Columns are period end dates